Global

All indications are that the July 2016 deadline for transition from Europe's eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) to the new Identification of Medicinal Products (IDMP) is not achievable. Sophie Daniels reports.

Although questions around sustainability still cloud Peru’s transition to a modern healthcare system, there is no doubt that the country’s economic resurgence in recent years is having a positive impact on Peru’s pharmaceutical infrastructure.

Despite recent challenges, the Australian market still offers a number of opportunities for pharma manufacturers.

With Ireland’s signing of a vaccine procurement agreement this month, the EU’s move toward joint action on medicine acquisition is gathering pace, writes Reflector.

With the talk shifting (again) to a Greek exit from the Eurozone, what is pharma thinking?

With the perception of Morocco as just a local healthcare market waning, the country is focused on forging partnerships with other african nations and developing its pharma industrial base and export capabilities.

While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.

NICE's proposed Innovation Office emerges with a new name. Leela Barham reports.

Reflector looks at the revitalized European Union directive on patients’ rights in cross-border healthcare.

Following the Conservatives surprise majority win in the UK election, Leela Barham asks what does it mean for pharma?

EUnetHTA has developed guidelines to help “set a general framework for EUnetHTA on how to conduct economic evaluations”, arguably HTA's most controversial element. Leela Barham reports.

Novartis announces that its lung cancer drug, Zykadia, gained European Union approval.

Tapping into the fast-growing and lucrative “multicultural” segment requires new and more aggressive approaches to brand planning and consumer engagement.

Edging through the complex terrain that is health technology assessment in Europe

Scott Lewin looks at Brazil's recently expanded transparency inititatives and how they affect pharma companies doing business in the region.

Once focused mainly on generic medicines, Korea’s pharma sector has leveraged significant new investments in R&D to transform itself into a true player in the global market-with aspirations as a future top-tier contributor to new medicines innovation.

William Looney speaks to Dr. Claudia Graeve, who leads the Healthcare Businesswomen's Association's sole international chapter in Europe, on improving the prospects for female managers in the region.

CPhI report notes that the Indonesian pharma market is on the brink of a regional manufacturing boom, with market capitalizations and company values rising.

Reflector edges through the complex terrain that is health technology assessment in Europe.

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London.

The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.

Leela Barham looks at what the rival parties are promising for healthcare ahead of the UK General Election next month.

As the prevalence of falsified medicines continues to increase, Switzerland is taking measures to secure its supply chain such as the implementation of serialization.

Hope abounds for local drug discovery companies despite challenges at home.

That the UK's NHS has struck a deal for a national roll-out of Bexsero, GSK's vaccine for Meningitis B in infants, is good, but it needs to do better, writes Leela Barham.

In yet another demonstration of how far drug pricing concerns are invading the hitherto sacrosanct territory of drug development, a consortium of national advisory bodies on pricing have written to the chief official responsible for European Union drug research.

Dr. Anuj Gupta explains the potential implications of the GST- or the goods and services tax - on Indian pharma.

The EU’s proposed new study on off-label prescribing is just another way of kicking the subject into the long grass.

Energy reform may be stealing the headlines in Mexico, but a rising regulatory authority, the beginnings of healthcare reform, and cost-competitive manufacturing are fueling future growth in the country’s pharma industry-for domestic and global players alike.

The results of this year’s survey indicate that the media’s scrutiny of pharma increased in 2014,with drug safety again again sitting atop of the list of hot button issues.